{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-280509","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.561044+00:00","generated_at":"2026-05-29T02:21:47.936029+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Soleno Therapeutics secures up to $200M debt financing from Oxford Finance; initial $50M drawn","bullets":["Initial $50 million draw at closing; up to $100 million in milestone tranches tied to FDA approval of DCCR for PWS.","Pro-forma cash, equivalents and marketable securities of $334.7 million as of September 30, 2024 including the draw.","Loan terms: 48-month interest-only period, 60-month maturity (extendable 12 months), floating rate of 1-month SOFR + 5.50%.","Proceeds to support commercial launch activities for DCCR (diazoxide choline) extended-release tablets for Prader-Willi syndrome.","Covenants include minimum cash (starting June 30, 2025) and revenue triggers; loan secured by substantially all assets including IP."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-280509","json":"https://secwatch.observer/filing/0001193125-24-280509.json","markdown":"https://secwatch.observer/filing/0001193125-24-280509.md","text":"https://secwatch.observer/filing/0001193125-24-280509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524280509/0001193125-24-280509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524280509/d903020d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:21:47.936029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}